Table 4. Laboratory findings and treatment of patients

|  | | **Patients with T2DM** | | | **Patients without T2DM** | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Characteristic** | **Survivor** (n = 114) | **Non-survivor** (n = 93) | **p value**1 | **Survivor** (n = 322) | **Non-survivor** (n = 299) | **p value**2 |
| Laboratory findings | WBC (×109/L), Median (IQR) | 9.6 (6.9 – 14.2) | 12.4 (9.6 – 17.3) | **<0.001** | 9.8 (7.2 – 13.8) | 12.5 (8.6 – 16.7) | **<0.001** |
|  | Unknown | 5 | 6 |  | 16 | 19 |  |
|  | WBC (×109/L), n (%) |  |  | **0.003** |  |  | **<0.001** |
|  | 4-10 | 52 (48) | 22 (25) |  | 146 (48) | 80 (29) |  |
|  | < 4 | 6 (5.5) | 4 (4.6) |  | 10 (3.3) | 13 (4.6) |  |
|  | 10 | 51 (47) | 61 (70) |  | 150 (49) | 187 (67) |  |
|  | Unknown | 5 | 6 |  | 16 | 19 |  |
|  | Neutrophils (×109/L), Median (IQR) | 8.0 (5.0 – 12.5) | 11.2 (8.3 – 16.1) | **<0.001** | 8.1 (5.2 – 11.8) | 10.8 (7.2 – 15.0) | **<0.001** |
|  | Unknown | 5 | 9 |  | 20 | 23 |  |
|  | Neutrophils (×109/L), n (%) |  |  | **0.004** |  |  | **<0.001** |
|  | <= 6.3 | 43 (38) | 18 (19) |  | 130 (40) | 79 (26) |  |
|  | 6.3 | 71 (62) | 75 (81) |  | 192 (60) | 220 (74) |  |
|  | Lymphocytes (×109/L), Median (IQR) | 0.9 (0.7 – 1.4) | 0.9 (0.4 – 1.2) | **0.009** | 1.1 (0.7 – 1.6) | 0.8 (0.6 – 1.1) | **<0.001** |
|  | Unknown | 5 | 9 |  | 20 | 23 |  |
|  | Lymphocytes (×109/L), n (%) |  |  | 0.72 |  |  | **<0.001** |
|  | = 1 | 58 (51) | 45 (48) |  | 193 (60) | 111 (37) |  |
|  | < 1 | 56 (49) | 48 (52) |  | 129 (40) | 188 (63) |  |
|  | NLR, Median (IQR) | 8.4 (4.2 – 15.5) | 13.6 (8.0 – 26.8) | **<0.001** | 7.4 (4.1 – 14.0) | 12.8 (7.6 – 19.9) | **<0.001** |
|  | Unknown | 5 | 9 |  | 20 | 23 |  |
|  | NLR, n (%) |  |  | **0.001** |  |  | **<0.001** |
|  | < 5.86 | 40 (37) | 13 (15) |  | 120 (40) | 38 (14) |  |
|  | = 5.86 | 69 (63) | 71 (85) |  | 182 (60) | 238 (86) |  |
|  | Unknown | 5 | 9 |  | 20 | 23 |  |
|  | Platelets (×109/L), Median (IQR) | 183.5 (137.0 – 216.0) | 264.5 (85.6 – 298.0) | **<0.001** | 173.0 (99.2 – 216.0) | 259.0 (59.0 – 296.0) | **<0.001** |
|  | Unknown | 0 | 3 |  | 3 | 17 |  |
|  | Platelets (×109/L), n (%) |  |  | 0.75 |  |  | 0.23 |
|  | = 125 | 88 (77) | 70 (75) |  | 223 (69) | 220 (74) |  |
|  | < 125 | 26 (23) | 23 (25) |  | 99 (31) | 79 (26) |  |
| Blood gas findings | SaO2 (%), Median (IQR) | 92.0 (89.0 – 95.0) | 85.5 (79.0 – 91.0) | **<0.001** | 92.0 (86.0 – 95.0) | 85.0 (75.0 – 90.0) | **<0.001** |
|  | Unknown | 0 | 1 |  | 5 | 5 |  |
|  | SaO2, n (%) |  |  | **<0.001** |  |  | **<0.001** |
|  | = 90 | 82 (72) | 31 (33) |  | 201 (62) | 94 (31) |  |
|  | < 90 | 32 (28) | 62 (67) |  | 121 (38) | 205 (69) |  |
|  | FiO2 (%), Median (IQR) | 21.0 (21.0 – 28.0) | 21.0 (21.0 – 34.0) | 0.69 | 21.0 (21.0 – 21.0) | 21.0 (21.0 – 80.0) | **<0.001** |
|  | Unknown | 5 | 5 |  | 12 | 21 |  |
|  | FiO2 (%), n (%) |  |  | 0.91 |  |  | **0.002** |
|  | 21 (O2 therapy) | 29 (25) | 23 (25) |  | 72 (22) | 100 (33) |  |
|  | 21 | 85 (75) | 70 (75) |  | 250 (78) | 199 (67) |  |
|  | PaO2:FiO2 ratio, Median (IQR) | 249.0 (159.0 – 338.0) | 139.0 (84.3 – 250.5) | **<0.001** | 217.0 (132.0 – 327.0) | 106.5 (71.0 – 201.0) | **<0.001** |
|  | Unknown | 5 | 5 |  | 41 | 15 |  |
|  | PaO2:FiO2 ratio, n (%) |  |  | **<0.001** |  |  | **<0.001** |
|  | 200 | 72 (63) | 35 (38) |  | 194 (60) | 86 (29) |  |
|  | <= 200 | 42 (37) | 58 (62) |  | 128 (40) | 213 (71) |  |
|  | Calculated PaO2:FiO2 ratio, Median (IQR) | 3.5 (2.6 – 4.3) | 2.8 (1.7 – 3.8) | **0.009** | 3.3 (2.5 – 4.2) | 2.6 (1.1 – 3.6) | **<0.001** |
|  | Unknown | 9 | 9 |  | 49 | 35 |  |
|  | Calculated PaO2:FiO2 ratio, n (%) |  |  | 0.65 |  |  | 0.20 |
|  | 200 | 9 (7.9) | 9 (9.7) |  | 49 (15) | 35 (12) |  |
|  | <= 200 | 105 (92) | 84 (90) |  | 273 (85) | 264 (88) |  |
|  | PaO2 (mmHg), Median (IQR) | 78.2 (67.2 – 101.0) | 67.4 (54.0 – 87.6) | **<0.001** | 77.7 (64.5 – 96.0) | 64.2 (50.2 – 84.2) | **<0.001** |
|  | Unknown | 6 | 6 |  | 39 | 16 |  |
|  | PaO2, n (%) |  |  | **<0.001** |  |  | **<0.001** |
|  | = 60 | 102 (89) | 61 (66) |  | 278 (86) | 183 (61) |  |
|  | < 60 | 12 (11) | 32 (34) |  | 44 (14) | 116 (39) |  |
| Treatment | Corticosteroids, n (%) | 86 (75) | 78 (84) | 0.14 | 279 (87) | 272 (91) | 0.089 |
|  | Anticoagulants, n (%) | 103 (90) | 81 (87) | 0.46 | 279 (87) | 270 (90) | 0.16 |
|  | Antimalarials, n (%) | 61 (54) | 49 (53) | 0.91 | 171 (53) | 148 (49) | 0.37 |
|  | Pronation, n (%) | 41 (41) | 40 (43) | 0.82 | 136 (49) | 138 (47) | 0.61 |
|  | Unknown | 15 | 0 |  | 43 | 3 |  |
| 1Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test | | | | | | | |
| 2Wilcoxon rank sum test; Pearson's Chi-squared test | | | | | | | |